The International Collaboration on Cosmetics Safety ushers in a new phase as its 2026 Board officers take their roles, strengthening its worldwide dedication to promoting animal-free innovations in cosmetics safety science amid swift regulatory and scientific shifts.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the nexus of science, policy, and cooperative action, uniting varied stakeholders who pursue the shared goal of advancing the worldwide shift toward animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers highlights the organization’s commitment to preserving strategic direction as it navigates an increasingly intricate global landscape, where expectations surrounding ethical research, scientific precision, and regulatory coherence continue to advance.
Continued leadership stability and expansive global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Together, the officers form a Board leadership team that spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than advocacy for any single sector. This balance is central to the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Driving progress in animal-free science through collective collaboration
At the heart of ICCS’ mission is the belief that animal-free approaches to safety assessment are not only ethically preferable but scientifically superior when properly developed and validated. Since its formation in early 2023, ICCS has worked to demonstrate that non-animal methods can provide reliable, relevant information for protecting both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining traction, supported by tangible outputs and growing engagement from regulators around the world.
Throughout 2025, ICCS introduced a range of initiatives that reinforced its scientific base and broadened its reach. Among these efforts was the publication of a Best Practice Guidance document, created to offer clearer direction and greater uniformity in applying animal-free safety assessment methods. The guidance sought to connect scientific advances with regulatory needs, delivering a practical framework that stakeholders could use when generating or reviewing non‑animal evidence.
In parallel, ICCS also played a key role in shaping innovative methodologies that align with next generation risk assessment (NGRA), an evolving framework that integrates advanced in vitro, in silico, and exposure-led approaches. These techniques are increasingly viewed as essential to modern toxicology, offering more human-relevant insights while reducing reliance on animal testing. ICCS’ efforts in this field highlight its commitment to ethical advancement and scientific excellence.
ICCS has also placed strong emphasis on maintaining ongoing dialogue. Throughout 2025, the organization engaged in wide-ranging interactions with regulators, scientists, and policymakers across multiple regions, guiding discussions on how animal‑free data might be assessed and integrated into existing regulatory frameworks. These exchanges have been essential in building shared understanding and trust, particularly in areas where the incorporation of non‑animal methodologies is still progressing.
A pivotal moment for cosmetics safety regulation
The installation of the 2026 Board officers takes place during a phase marked by notable transformations in global cosmetics regulations, as many markets reassess long‑standing testing standards in response to public expectations, scientific advancements, and new international policy trends, and within this shifting environment, organizations like ICCS remain vital in aligning innovation with regulatory requirements to ensure that progress continues to be both reliable and sustainable.
ICCS leadership has consistently emphasized that progress in animal-free safety science cannot arise from isolated efforts; instead, it requires coordinated action among industry, academia, regulators, and civil society. This perspective is reflected in the composition of the Board, which brings together leaders who understand the technical, regulatory, and organizational dimensions necessary to foster significant transformation.
ICCS leadership statements after the elections conveyed a blend of confidence and pragmatism. They noted the progress achieved in recent years while recognizing that substantial challenges persist. Securing broad regulatory endorsement for animal-free methodologies will demand sustained research investment, open data dissemination, and continuous collaboration with authorities to respond to valid concerns about reliability, real-world relevance, and safeguarding public health.
The re-elected Chair emphasized the vital need to rely on ICCS’ global, multi-stakeholder framework to close the gap between innovation and regulation, ensuring that advances in animal-free science extend beyond the laboratory and evolve into dependable, consistently implemented tools that regulators can trust.
Reinforcing the groundwork for lasting influence
As ICCS moves toward 2026 and the years that follow, the organization aims to reinforce its progress while broadening its influence, and the newly appointed Board leadership is anticipated to guide key priorities that balance scientific aspirations with practical execution, including pinpointing topics that require further direction or consensus, backing the validation and dissemination of emerging methodologies, and promoting global harmonization to minimize fragmentation among regulatory expectations.
Education remains another key pillar of ICCS’ strategy. By providing accessible, science-based resources and forums for discussion, the organization aims to demystify animal-free safety science and encourage informed decision-making. This is particularly important in a field where misconceptions or uneven understanding can slow progress, even when the underlying science is sound.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Based in New York, ICCS continues to operate as a global initiative, highlighting the international scope of cosmetic innovation and regulatory supervision. As products and their components move across borders, harmonized guidelines and mutual recognition of safety protocols become increasingly vital. Through collaborative efforts, ICCS seeks to encourage this coherence, reduce duplicated work, and reinforce trust in animal-free science worldwide.
By confirming its 2026 Board officers, ICCS underscores both consistency and a clear drive toward progress, with a leadership group that extends the momentum of a year defined by tangible accomplishments while offering the insight and expertise required to steer the coming stage of transformation; as scientific innovation quickens and regulatory expectations shift, the organization’s function as a unifying force and driver of animal-free cosmetics safety science is poised to gain even greater significance.
Ultimately, the significance of the 2026 Board elections lies not only in the individuals appointed, but in what their leadership represents: a sustained commitment to collaboration, scientific integrity, and the responsible advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to translate vision into lasting impact, shaping the future of cosmetics safety in a way that aligns ethics, science, and global public trust.
